SM
SRPT icon

Sabby Management’s Sarepta Therapeutics SRPT Stock Holding History

Sabby Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-44
Closed -$618K – 145
2020
Q3 		$618K Buy
+44
New +$6.69K 0.09% 80
2019
Q1 		– Sell
-1,746
Closed -$19.1M – 122
2018
Q4 		$19.1M Hold
1,746
– – 4.19% 7
2018
Q3 		$28.2M Sell
1,746
-371
-18% -$50.7K 3.61% 8
2018
Q2 		$28M Sell
2,117
-216
-9% -$20.4K 4.32% 7
2018
Q1 		$17.3M Sell
2,333
-6,690
-74% -$446K 2.06% 9
2017
Q4 		$50.2M Buy
9,023
+1,760
+24% +$93.2K 4.57% 8
2017
Q3 		$32.9M Buy
7,263
+1,617
+29% +$64.6K 2.15% 12
2017
Q2 		$19M Buy
5,646
+1,597
+39% +$52K 1.25% 15
2017
Q1 		$12M Buy
4,049
+3,438
+563% +$106K 0.65% 30
2016
Q4 		$1.68M Sell
611
-2,915
-83% -$117K 0.1% 117
2016
Q3 		$21.7M Sell
3,526
-11,699
-77% -$354K 0.81% 24
2016
Q2 		$29M Buy
15,225
+14,032
+1,176% +$260K 1.51% 15
2016
Q1 		$2.33M Sell
1,193
-1,669
-58% -$29.2K 0.12% 87
2015
Q4 		$11M Sell
2,862
-3,809
-57% -$124K 0.61% 30
2015
Q3 		$21.4M Sell
6,671
-52
-0.8% -$1.76K 0.88% 20
2015
Q2 		$20.5M Sell
6,723
-544
-7% -$11.1K 0.75% 25
2015
Q1 		$9.65M Buy
7,267
+695
+11% +$9.26K 0.4% 45
2014
Q4 		$9.51K Buy
6,572
+2,998
+84% +$50.8K 0.3% 40
2014
Q3 		$7.54K Buy
3,574
+1,936
+118% +$43.7K 0.29% 51
2014
Q2 		$4.88M Buy
1,638
+1,287
+367% +$40.7K 0.21% 62
2014
Q1 		$843K Sell
351
-1,756
-83% -$44.8K 0.05% 147
2013
Q4 		$4.29M Sell
2,107
-602
-22% -$17.9K 0.27% 54
2013
Q3 		$12.8M Buy
2,709
+450
+20% +$17.3K 0.83% 32
2013
Q2 		$8.6M Buy
+2,259
New +$80.8K 0.57% 41

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Sabby Management's SRPT Position: Q1 2017 in Review

Sabby Management sold out of Sarepta Therapeutics (SRPT) in Q1 2017, closing a stake of 2,014,787 shares — an estimated $62.4M sold.

Sabby Management first reported a position in SRPT in Q2 2013 and held it in 13 quarters. The position peaked at $55.3M in Q4 2016. 179 funds tracked by Wall St. Rank hold SRPT as of Q1 2017.

  • Sabby Management reported no remaining Sarepta Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Sabby Management sold 2,014,787 Sarepta Therapeutics shares in Q1 2017, an estimated $62.4M.
  • Sabby Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 13 quarters.
  • Sabby Management's Sarepta Therapeutics position peaked at $55.3M in Q4 2016.
  • 179 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.